Results. Patient characteristics were well balanced between the 3 groups ( Table 2). Analyses were performed at median follow-up times of 33, 47, and 68 months. [25,26,27] Results showed no ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

Electromagnetic induction (EI), or the production of voltage across a conductor by varying the magnetic field or by moving the conductor through a fixed magnetic field, is one of the most traditional ...

There’s been no shortage of blockbuster deals as the J.P. Morgan Healthcare Conference kicked off Monday in San Francisco, and now Eli Lilly has joined the fray, setting down $1 billion up front for ...

Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...